![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1538654
¼¼°èÀÇ Àΰø ¸Á¸· ÀÓÇöõÆ® ½ÃÀå ±Ô¸ð Á¶»ç : Á¦Ç° À¯Çüº°, ¿ëµµº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)Global Artificial Retina Implant Market Size study, by Product Type (Epiretinal Implants, Subretinal Implants, Suprachoroidal Implants), by Application (Age-Related Macular Degeneration (AMD), Retinitis Pigmentosa) and Regional Forecasts 2022-2032 |
¼¼°è Àΰø ¸Á¸· ÀÓÇöõÆ® ½ÃÀåÀº 2023³â ¾à 13¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³âºÎÅÍ 2032³â±îÁö 20.96% ÀÌ»óÀÇ °ßÁ¶ÇÑ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Àΰø ¸Á¸· ÀÓÇöõÆ®´Â ¸Á¸· ÁúȯÀ¸·Î ÀÎÇÑ ½Ç¸íÀ¸·Î °íÅë¹Þ´Â »ç¶÷µé¿¡°Ô ºÎºÐÀûÀÎ ½Ã·ÂÀ» ȸº¹Çϵµ·Ï ¼³°èµÇ¾î ÀÇ·á ºÐ¾ß¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ÀÌ ÀÓÇöõÆ®´Â ÷´Ü ±â¼úÀ» Ȱ¿ëÇÏ¿© ¼Õ»óµÈ ¸Á¸· ¼¼Æ÷¸¦ ¿ìȸÇÏ¿© ½Ã°¢ Á¤º¸¸¦ ³ú¿¡ Àü´ÞÇÕ´Ï´Ù. ³ëȼº Ȳ¹Ýº¯¼º(AMD) ¹× ¸Á¸·»ö¼Òº¯¼ºÁõ ȯÀÚ ¼öÀÇ Áõ°¡¿Í ¸Á¸· ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, ½Å»ý ±â¾÷ Ȱµ¿ÀÇ ±ÞÁõ°ú ÁÖ¿ä ±â¾÷ °£ÀÇ Àü·«Àû Á¦ÈÞ°¡ ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
Àü ¼¼°èÀûÀ¸·Î AMD¿Í ¸Á¸·»ö¼Òº¯¼ºÁõÀÇ À¯º´·üÀº ÁÖ·Î °í·ÉÈ·Î ÀÎÇØ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±âÁ¸ Ä¡·á¹ýÀ¸·Î´Â ÃæºÐÇÏÁö ¾ÊÀº °æ¿ì°¡ ¸¹¾Æ Àΰø ¸Á¸· ÀÓÇöõÆ®¿Í °°Àº Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)¿¡ µû¸£¸é, 2019³â 40¼¼ ÀÌ»ó ¹Ì±¹ÀÎ ¾à 1,980¸¸ ¸íÀÌ AMD¸¦ ¾Î°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Æ¢ºù°Õ ´ëÇк´¿ø ¹× Àǰú´ëÇп¡ µû¸£¸é, µ¶ÀÏ¿¡¼´Â 2021³â ¾à 50¸¸ ¸íÀÇ AMD ȯÀÚ°¡ ¹ß»ýÇÒ °ÍÀ¸·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ¼è¾àÇØÁø ½Ã·ÂÀ» ȸº¹½ÃÄÑ¾ß ÇÏ´Â ½É°¢ÇÑ Çʿ伺À¸·Î ÀÎÇØ ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ÀÓÇöõÆ® ºñ¿ë°ú ¼ö¼ú ÇÕº´Áõ µîÀÇ ¹®Á¦´Â 2024-2032³â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼¼°è Àΰø ¸Á¸· ÀÓÇöõÆ® ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀ¸·Î´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«°¡ ÀÖÀ¸¸ç, 2023³â¿¡´Â AMDÀÇ ³ôÀº ¹ßº´·ü°ú Argus II¿Í °°Àº FDA ½ÂÀÎ ÀÓÇöõÆ® Á¦Ç°ÀÇ Á¸Àç·Î ÀÎÇØ ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ Áö¿ª. ÀÌ Áö¿ªÀº Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºêÀÇ °·ÂÇÑ Áö¿ø, ÁÖ¿ä ¿¬±¸ ±â°ü ¹× ¾È°ú ¼¾ÅÍÀÇ È®¸³µÈ ³×Æ®¿öÅ©ÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ôÀº °¡Ã³ºÐ ¼Òµæ°ú ¸Á¸· ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç°ú ±â¼ú ¹ßÀüÀº ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖÀ¸¸ç, ºÏ¹Ì´Â Àΰø ¸Á¸· ÀÓÇöõÆ® ºÐ¾ßÀÇ ¼±µÎÁÖÀÚ·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. À¯·´ ¿ª½Ã Àü·«Àû ÆÄÆ®³Ê½Ê°ú ÀÓ»ó½ÃÇèÀ» ÅëÇØ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ±Þ¼ÓÇÑ °í·ÉÈ¿Í ÇコÄɾî ÅõÀÚ Áõ°¡¿¡ ÈûÀÔ¾î °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ½ÃÀåÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The Global Artificial Retina Implant Market is valued at approximately USD 1.31 billion in 2023 and is projected to grow with a healthy growth rate of over 20.96% over the forecast period 2024-2032. Artificial retina implants, designed to restore partial vision to those suffering from blindness due to retinal diseases, have revolutionized the medical field. These implants leverage advanced technology to bypass damaged retinal cells, thereby transmitting visual information to the brain. The rising incidences of age-related macular degeneration (AMD) and retinitis pigmentosa, coupled with increasing investments in retinal research, are key drivers propelling the growth of this market. Moreover, the surge in startup activities and strategic collaborations among major players further bolster market expansion.
The prevalence of AMD and retinitis pigmentosa is escalating globally, primarily driven by an aging population. Conventional treatments often fall short, thereby amplifying the demand for innovative solutions like artificial retina implants. According to the Centers for Disease Control and Prevention, approximately 19.8 million Americans aged 40 and older were affected by AMD in 2019. In addition, the University Hospital and Faculty of Medicine Tubingen reported that Germany had around 500,000 AMD sufferers in 2021. Furthermore, the market is experiencing substantial growth, driven by the critical need to restore vision in individuals affected by these debilitating conditions. However, challenges such as high costs of implants and surgical complications can restrain the growth of the market during the forecast period 2024-2032.
The key regions in the Global Artificial Retina Implant Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, North America holds the largest market share due to the high incidence of AMD and the presence of FDA-approved implant products such as Argus II. The region benefits from strong support from government initiatives, leading research institutions, and a well-established network of ophthalmic centers. Additionally, high disposable incomes and a growing prevalence of retinal diseases contribute to market growth. Innovative solutions and technological advancements further propel the demand, making North America a leader in the artificial retina implant sector. Europe is also showing substantial growth, driven by strategic partnerships and clinical trials. The Asia-Pacific region is poised to be the fastest-growing market, propelled by a rapidly aging population and increasing healthcare investments.